Founded in 2016, the goal of the company is to develop a treatment for the 84 million Americans who suffer from excessive sweating and hyperhidrosis. We have raised funding, filed patents in the U.S. and globally, cultivated the product design as well as refined its manufacturing process, and entered pre-clinical human trials of the CDX-101 device in early 2018. Our device has proven to reduce excessive sweating in multiple areas of the body for up to six weeks – a dramatic difference from other available treatments without the often expensive or painful side effects. We anticipate the device to be commercially available in 2018 for medical professionals to use with patients.
San Francisco, CA, USAcandesant.com
Inaccurate data? Flag it here.
Open jobs at Candesant Biomedical